<DOC>
	<DOCNO>NCT00620243</DOCNO>
	<brief_summary>We hypothesize 18FDG Positron Emission Tomography ( FDG PET ) imaging , carry first cycle chemotherapy , identify responder , thus permit early termination potential toxic therapy non- responder lead significant decrease morbidity cost . The value PET image early predictor response chemotherapy show cancer .</brief_summary>
	<brief_title>Pilot Study Evaluate 18F-fluorodeoxyglucose ( FDG ) Positron Emission Tomography /Computed Tomography ( PET/CT ) Prediction Early Response Chemotherapy Ovarian Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Histologically proven ovarian cancer diagnosis stage . Patients evidence disease radiographically measurable ( CT scan ) Patients plan undergo standard chemotherapy . Dose schedule determine per treat physician Patients malignancy active within 5 year except nonmelanoma skin cancer , carcinoma situ cervix . Patients active infection Patients childbearing potential exclude study . Patients expect survival &lt; 3 month . Patients plan able receive outline chemotherapy regimen part standard practice . Patient unable complete study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>PET</keyword>
	<keyword>CT</keyword>
	<keyword>04-064</keyword>
</DOC>